ABSTRACT: ObjectiveWe observe the curative effect, median survival time, time to progression, quality of life and adverse effect of patients
with advanced refractory non-small cell lung cancer (NSCLC) after gefitinib (Iressa) treatment.
MethodsForty-one patients with grade IIIb to IV NSCLC previously treated with two chemotherapy including 85.4% of patients after
second line therapy were chosen. The regimen was oral intake of gefitinib 250 mg once daily until the disease progression
or toxic reaction has become intolerable. The patients were required to receive tumor evaluation before the treatment, one
month, two month and every three months after Iressa administration.
ResultsAll of 41 patients were evaluable for therapeutic effect. Without complete regression being observed, partial response rate
(PR), stable disease (SD) and progression of disease (PD) were 43.9% (18/41), 34.1% (14/41) and 22.1% (9/41), respectively.
The overall response rate was 43.9% (18/41) and disease control rate (PR + SD) was 78% (32/41). The response rate in male
was 42.1%, while it in female was 45.5% (P > 0.05). Twenty-two of them (53.7%, 22/41) were still alive with 10.1 months of MST when the follow-up ended in November
2006. TTP and MST of patients who died was 2.7 and 5.0 months, respectively. The rate of symptom improvement was 78% of all
patients with 13 months of MST of PR patients. The Karnofsky enhanced 20 ± 5 after 28 days treatment without 3–4 degree of
ConclusionIressa has significant antitumor activity in advanced NSCLC patients who have previously failed in second or third line chemotherapy.
Iressa is effective and safe for patients with poor performance status.
The Chinese-German Journal of Clinical Oncology 05/2012; 8(6):314-316.
ABSTRACT: ObjectiveTo identify the differences between cavitating squamous cell lung carcinoma (cSLC) and non-cavitating squamous cell lung carcinoma
MethodsFifty-one patients with cSLC and 281 with ncSLC confirmed by surgery in our hospital between 1999 to 2000 were collected and
their clinical, histological and survival features were retrospectively analyzed.
ResultsPatients with cSLC had more frequent manifestation of infection and weight loss. They usually experienced longer duration
of pre-diagnosis and showed bigger tumor mass, larger primary tumor invasion with worse differentiated than ncSLC patients.
There was no significant difference in age, sex, smoking history, family tumor history, personal tuberculosis history, disease
location, TNM stage, lymph node invasion, and metastasis between the two groups. Median survival time was 29 months for cSLC
and 35 months for ncSLC. One-and 3-year survival rates were 86.3% and 43.1% for cSLC vs. 91.1% and 47.0% for ncSLC respectively
ConclusionPatients with cSLC presented with a bigger mass, a larger extent of primary tumor invasion, worse differentiated, more obstructed
pneumonia that might result in longer duration of pre-diagnosis and more weight loss. As lack of differences in disease stages,
lymph node invasion, metastasis and especially survival time with ncSLC, cSLC couldn’t be classified as a special type of
squamous cell carcinoma by present evidences.
The Chinese-German Journal of Clinical Oncology 04/2012; 6(2):187-190.
ABSTRACT: New therapeutic approaches are being developed based on the findings that several genetic abnormalities underlying non-small-cell lung cancer (NSCLC) could influence chemosensitivity. In this study, we assessed whether polymorphisms in genes of nucleotide excision repair (NER) pathway, including ERCC5, ERCC6, MMS19L, CCNH, XPC, RRM1, can affect the tolerability of platinum-based chemotherapy in NSCLC patients. We used AllGloTM probe to assess genotyping and polymorphisms in 388 stage IIIB and IV NSCLC patients treated with platinum-based chemotherapy. MMS19L might be associated with the adverse events of chemotherapy in NSCLC, especially for all grade leucopenia (P = 0.020), all grade jaundice (P = 0.037) and all grade creatinine increasing (P = 0.013). In terms of grade 3/4 adverse events, MMS19L was related with total grade 3/4 adverse events (P = 0.024) and grade 3/4 thrombocytopenia (P = 0.035), while RRM1 was related with total grade 3/4 adverse events (P = 0.047) and grade 3/4 vomiting (P = 0.046). ERCC5 was related with more infection (P = 0.017). We found that some SNPs in NER pathway genes were correlated with toxicity treated with double chemotherapy in advanced NSCLC patients, especially for SNPs of MMS19L, RRM1 and ERCC5.
PLoS ONE 01/2012; 7(10):e48350. · 4.09 Impact Factor
ABSTRACT: Gefiinib and erlotinib are two similar small molecules of selective and reversible epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), which have been approved for second-line or third-line indication in previously treated advanced Non-small-cell lung cancer (NSCLC) patients. The results of comparing the EGFR-TKI with standard platinum-based doublet chemotherapy as the first-line treatment in advanced NSCLC patients with activated EGFR mutation were still controversial. A meta-analysis was performed to derive a more precise estimation of these regimens. Finally, six eligible trials involved 1,021 patients were identified. The patients receiving EGFR-TKI as front-line therapy had a significantly longer progression-free survival (PFS) than patients treated with chemotherapy [median PFS was 9.5 versus 5.9 months; hazard ratio (HR)=0.37; 95% confidence intervals (CI)=0.27-0.52; p<0.001]. The overall response rate (ORR) of EGFR-TKI was 66.60%, whereas the ORR of chemotherapy regimen was 30.62%, which was also a statistically significant favor for EGFR-TKI [relative risk (RR)=5.68; 95% CI=3.17-10.18; p<0.001]. The overall survival (OS) was numerically longer in the patients received EGFR-TKI than patients treated by chemotherapy, although the difference did not reach a statistical significance (median OS was 30.5 vs. 23.6 months; HR=0.94; 95% CI=0.77-1.15; p=0.57). Comparing with first-line chemotherapy, treatment of EGFR-TKI achieved a statistical significantly longer PFS, higher ORR and numerically longer OS in the advanced NSCLC patients harboring activated EGFR mutations, thus, it should be the first choice in the previously untreated NSCLC patients with activated EGFR mutation.
International Journal of Cancer 12/2011; 131(5):E822-9. · 5.44 Impact Factor
ABSTRACT: To investigate the relationship between cytokine level and cancer cachexia on murine model, and to observe the effects of regular dose of indomethacin on cancer cachexia and survival of mice.
C57 mice bearing Lewis lung carcinoma were used to establish murine cancer cachexia model. The serum cytokine levels (IL-1, IL-6, TNF-α and IFN-γ) and body weight of the mice were measured at different time points before and after treatment with daily intraperioneal injection of either indomethacin (1 mg/kg) or saline.
The mice in cancer cachexia group had significantly higher serum levels of IL-1, IL-6 and TNF-α ( P < 0.05) and lower body weight ( P < 0.05) than those in healthy control group. Compared to saline treatment, indomethacin intervention apparently down regulated the levels of IL-1, IL-6 and TNF-α ( P < 0.05 ), and remarkably prolonged the survival of mice ( P < 0.05). No significant difference in IFN-γ level was observed between cancer cachexia and healthy control groups ( P > 0.05), as well as between indomethacin and saline groups ( P > 0.05).
The results suggest that serum IL-1, IL-6 and TNF-α are possibly associated with cancer cachexia, however, IFN-γ seems to be irrelevant. Indomethacin may potentially ameliorate cancer cachexia through down-regulating levels of cytokines.
Zhongguo fei ai za zhi = Chinese journal of lung cancer 08/2004; 7(4):336-8.
ABSTRACT: The signal charge loss due to initial recombination and that due
to volume recombination have been measured separately using parallel
plate ionization chambers irradiated with cobalt-60 gamma rays, over a
wide range of applied voltage and air humidity. It is shown that both
initial and volume recombination depend on the electric field strength
and also on humidity through ion clustering reaction with water
molecules. In spite of the usual assumptions, a linear relation has not
been observed between the inverses of the signal current and applied
voltage for initial recombination, nor between the inverses of the
signal current and square of the applied voltage for volume
recombination. Methods and data which can be used for estimation of
initial and volume recombination losses of ions in ionization chambers
IEEE Transactions on Nuclear Science 07/1999; · 1.45 Impact Factor